Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of California, San Diego
Centre Oscar Lambret
Kura Oncology, Inc.
Columbia University
Taiho Pharmaceutical Co., Ltd.
AHS Cancer Control Alberta
M.D. Anderson Cancer Center
China Medical University Hospital
University of Nebraska
M.D. Anderson Cancer Center
Novartis
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Novartis
Novartis
Dana-Farber Cancer Institute
University of California, San Francisco
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Novartis
Novartis
Novartis
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Duke University
Asan Medical Center
University Health Network, Toronto
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Dong-A ST Co., Ltd.
City of Hope Medical Center
Oncology Specialists, S.C.
Indiana University
University of Southern California
Children's Oncology Group
University of Rochester
Novartis
Duke University
Barbara Ann Karmanos Cancer Institute
Duke University
Technical University of Munich
Duke University
The Cleveland Clinic
National Cancer Institute (NCI)
SCRI Development Innovations, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Virginia